Remus Pharmaceuticals Limited — Dividend/Bonus, 09-11-2024: Dividend

Remus Pharmaceuticals Limited reported strong financial results for the first half of FY25, with total revenue reaching ₹27,555.54 Lakhs, a 797.60% increase year-over-year. EBITDA rose to ₹233.78 Lakhs, reflecting 113.99% growth, while Profit After Taxes surged by 148.09% to ₹1,401.12 Lakhs. The Board also approved a 10% interim dividend, equating to ₹1.00 per equity share, with the record date set for November 20, 2024.